SEDI Insider filing browser
Filter by Company
×
Filter by $CAD Amount
×
Filter by Filing Type
Filter by Insider
×
 
Date Issuer Insider Transaction Amount New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
Filed 2021-07-06 19:44
Tx date 2021-06-29
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$150,963
+3,151,639 vol
$0.0479 each
9,628,533
Filed 2021-07-06 19:41
Tx date 2021-06-29
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$1,035,178
+21,611,238 vol
$0.0479 each
41,132,615
Filed 2021-07-06 19:37
Tx date 2021-06-29
$ASP
Acerus Pharmaceuticals Corporation
Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$136,316
+2,845,855 vol
$0.0479 each
7,969,472
Filed 2021-07-06 19:33
Tx date 2021-06-29
$ASP
Acerus Pharmaceuticals Corporation
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$95,053
+1,984,407 vol
$0.0479 each
4,446,723
Filed 2021-07-06 19:30
Tx date 2021-06-29
$ASP
Acerus Pharmaceuticals Corporation
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$185,469
+3,872,013 vol
$0.0479 each
9,494,722
Filed 2021-07-06 19:26
Tx date 2021-06-29
$ASP
Acerus Pharmaceuticals Corporation
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$209,551
+4,374,775 vol
$0.0479 each
10,013,137
Filed 2020-12-18 07:37
Tx date 2020-12-16
$ASP
Acerus Pharmaceuticals Corporation
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+1,569,291 vol
2,169,291
Filed 2020-12-18 07:34
Tx date 2020-12-16
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+3,961,218 vol
3,961,218
Filed 2020-12-18 07:32
Tx date 2018-05-01
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2020-12-18 07:29
Tx date 2020-12-16
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+1,569,291 vol
1,569,291
Filed 2020-12-18 07:28
Tx date 2020-06-23
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-12-18 07:25
Tx date 2020-12-16
$ASP
Acerus Pharmaceuticals Corporation
Cotton, Geoffrey David
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+1,569,291 vol
1,569,291
Filed 2020-12-18 07:24
Tx date 2020-05-04
$ASP
Acerus Pharmaceuticals Corporation
Cotton, Geoffrey David
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-12-18 07:14
Tx date 2020-12-16
$ASP
Acerus Pharmaceuticals Corporation
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+1,143,218 vol
2,462,316
Filed 2020-12-18 07:08
Tx date 2020-12-16
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+1,569,291 vol
4,484,463
Filed 2020-12-04 13:37
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
Common Shares
99 - Correction of information
$7,937
+317,514 vol
$0.025 each
927,092
Filed 2020-12-04 13:33
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$46,784
+1,871,380 vol
$0.025 each
5,464,133
Filed 2020-11-27 13:34
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$57,309
+2,292,371 vol
$0.025 each
Filed 2020-11-30 10:41
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$3,435
+137,431 vol
$0.025 each
401,278
Filed 2020-11-27 13:41
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$12,734,214
+509,368,574 vol
$0.025 each
1,376,502,750
Filed 2020-11-27 13:38
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$78,133
+3,125,327 vol
$0.025 each
4,551,727
Filed 2020-11-27 13:34
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$57,309
+2,292,371 vol
$0.025 each
5,885,124
Filed 2020-11-27 13:31
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$748.75
+29,950 vol
$0.025 each
487,450
Filed 2020-11-27 13:18
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$614.63
+24,585 vol
$0.025 each
71,785
Filed 2020-11-27 13:06
Tx date 2020-11-26
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$34,090
+1,363,616 vol
$0.025 each
11,835,322
Filed 2020-11-16 10:24
Tx date 2020-11-13
$ASP
Acerus Pharmaceuticals Corporation
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,000
+400,000 vol
$0.03 each
457,500
Filed 2020-09-14 14:34
Tx date 2020-09-09
$ASP
Acerus Pharmaceuticals Corporation
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$68,593
+1,319,098 vol
$0.052 each
1,319,098
Filed 2020-09-14 14:31
Tx date 2020-09-08
$ASP
Acerus Pharmaceuticals Corporation
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-08-17 16:49
Tx date 2020-08-12
$ASP
Acerus Pharmaceuticals Corporation
Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$303,830
+5,123,617 vol
$0.0593 each
5,123,617
Filed 2020-08-17 16:47
Tx date 2020-08-03
$ASP
Acerus Pharmaceuticals Corporation
Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-06-28 18:41
Tx date 2020-06-23
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Holder: Gale Bale (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
92,000
Filed 2020-06-28 18:41
Tx date 2020-06-23
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Holder: Elizabeth Carlson (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
106,657
Filed 2020-06-28 18:40
Tx date 2020-06-23
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
609,578
Filed 2020-06-28 18:39
Tx date 2020-06-23
$ASP
Acerus Pharmaceuticals Corporation
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
3,592,753
Filed 2020-04-02 18:07
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$187,490
+4,148,017 vol
$0.0452 each
5,622,709
Filed 2020-04-02 18:03
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$235,452
+5,209,137 vol
$0.0452 each
5,638,362
Filed 2020-04-02 17:59
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$837,166
+18,521,377 vol
$0.0452 each
19,521,377
Filed 2020-04-02 17:56
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$104,645
+2,315,172 vol
$0.0452 each
2,715,172
Filed 2020-04-02 17:42
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$104,645
+2,315,172 vol
$0.0452 each
2,915,172
Filed 2020-04-02 17:38
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$104,645
+2,315,172 vol
$0.0452 each
2,915,172
Filed 2020-04-02 17:33
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options
$104,645
+2,315,172 vol
$0.0452 each
2,940,172
Filed 2020-04-02 17:16
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$244,173
+5,402,068 vol
$0.0452 each
6,476,894
Filed 2020-03-11 11:53
Tx date 2020-03-11
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-25,000 vol
600,000
Filed 2020-02-21 17:04
Tx date 2020-02-21
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately

+749,230,776 vol
867,134,176
Filed 2019-12-13 14:18
Tx date 2019-03-10
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-25,000 vol
625,000
Filed 2019-12-13 14:16
Tx date 2018-04-26
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-25,000 vol
450,000
Filed 2019-12-13 14:15
Tx date 2017-03-12
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-25,000 vol
375,000
Filed 2019-12-13 14:14
Tx date 2016-07-16
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-25,000 vol
200,000
Filed 2019-12-12 10:24
Tx date 2019-03-10
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
52 - Expiration of options

-25,000 vol
625,000
Filed 2019-12-12 10:22
Tx date 2018-11-06
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
52 - Expiration of options

-25,000 vol
450,000
Filed 2019-11-04 10:38
Tx date 2019-11-01
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,600
+20,000 vol
$0.08 each
61,000
Filed 2019-11-04 10:38
Tx date 2019-10-21
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$85.00
+1,000 vol
$0.085 each
41,000
Filed 2019-10-17 15:53
Tx date 2019-10-17
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,350
+130,000 vol
$0.095 each
10,471,706
Filed 2019-08-12 10:06
Tx date 2019-08-08
$ASP
Acerus Pharmaceuticals Corporation
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+429,225 vol
429,225
Filed 2019-08-12 10:04
Tx date 2019-05-31
$ASP
Acerus Pharmaceuticals Corporation
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2019-08-09 16:01
Tx date 2019-08-08
$ASP
Acerus Pharmaceuticals Corporation
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,860
+40,500 vol
$0.12 each
129,000
Filed 2019-08-09 15:56
Tx date 2019-08-08
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+324,826 vol
1,074,826
Filed 2019-08-09 15:49
Tx date 2019-08-08
$ASP
Acerus Pharmaceuticals Corporation
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+249,420 vol
1,474,692
Filed 2019-03-29
Tx date 2019-03-29
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately
$3,000,000
+15,384,616 vol
$0.195 each
117,903,400
Filed 2019-03-29
Tx date 2019-03-29
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$30,000
+153,847 vol
$0.195 each
263,847
Filed 2019-03-29
Tx date 2019-03-29
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$1,000,000
+5,128,206 vol
$0.195 each
10,341,706
Filed 2019-03-29
Tx date 2019-03-29
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately
$500,000
+2,564,103 vol
$0.195 each
4,558,730
Filed 2019-03-07
Tx date 2019-03-06
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options
$26,000
+200,000 vol
$0.13 each
675,000
Filed 2019-03-07
Tx date 2019-03-06
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$26,000
+200,000 vol
$0.13 each
725,000
Filed 2019-03-07
Tx date 2019-03-06
$ASP
Acerus Pharmaceuticals Corporation
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$26,000
+200,000 vol
$0.13 each
600,000
Filed 2019-03-07
Tx date 2019-03-06
$ASP
Acerus Pharmaceuticals Corporation
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$26,000
+200,000 vol
$0.13 each
600,000
Filed 2019-03-07
Tx date 2019-03-06
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$26,000
+200,000 vol
$0.13 each
400,000
Filed 2018-12-28
Tx date 2018-12-27
$ASP
Acerus Pharmaceuticals Corporation
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,135
+28,500 vol
$0.11 each
88,500
Filed 2018-12-26
Tx date 2018-12-24
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$49,463
+429,000 vol
$0.1153 each
1,994,627
Filed 2018-12-20
Tx date 2018-12-20
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$11,990
+100,000 vol
$0.1199 each
5,213,500
Filed 2018-12-17
Tx date 2018-12-17
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$29,315
+225,500 vol
$0.13 each
5,113,500
Filed 2018-12-11
Tx date 2018-12-10
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$2,632
+19,500 vol
$0.135 each
1,535,127
Filed 2018-12-11
Tx date 2018-12-11
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$4,117
+30,500 vol
$0.135 each
1,565,627
Filed 2018-12-07
Tx date 2018-12-07
$ASP
Acerus Pharmaceuticals Corporation
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,917
+14,200 vol
$0.135 each
47,200
Filed 2018-12-07
Tx date 2018-12-07
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$43,200
+320,000 vol
$0.135 each
1,515,627
Filed 2018-11-30
Tx date 2018-11-30
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,320
+14,500 vol
$0.16 each
109,500
Filed 2018-11-30
Tx date 2018-11-30
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$77.50
+500 vol
$0.155 each
110,000
Filed 2018-11-21
Tx date 2018-11-21
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,800
+10,000 vol
$0.18 each
95,000
Filed 2018-11-20
Tx date 2018-11-20
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,600
+10,000 vol
$0.16 each
85,000
Filed 2018-11-19
Tx date 2018-10-30
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-11-19
Tx date 2018-11-19
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+750,000 vol
750,000
Filed 2018-11-19
Tx date 2018-10-30
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-11-19
Tx date 2018-11-19
$ASP
Acerus Pharmaceuticals Corporation
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,750
+75,000 vol
$0.17 each
75,000
Filed 2018-09-11
Tx date 2018-09-10
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$22,560
+94,000 vol
$0.24 each
1,195,627
Filed 2018-09-11
Tx date 2018-09-07
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$5,760
+24,000 vol
$0.24 each
1,101,627
Filed 2018-09-07
Tx date 2018-09-07
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,640
+14,000 vol
$0.26 each
40,000
Filed 2018-08-31
Tx date 2018-08-29
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$560.00
+2,000 vol
$0.28 each
6,000
Filed 2018-08-31
Tx date 2018-08-30
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$5,600
+20,000 vol
$0.28 each
26,000
Filed 2018-08-29
Tx date 2018-08-28
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,120
+4,000 vol
$0.28 each
4,000
Filed 2018-08-29
Tx date 2017-12-06
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-29
Tx date 2018-08-28
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$115,199
+400,000 vol
$0.288 each
4,888,000
Filed 2018-08-28
Tx date 2018-08-28
$ASP
Acerus Pharmaceuticals Corporation
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$5,600
+20,000 vol
$0.28 each
60,000
Filed 2018-08-28
Tx date 2018-08-27
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$62,720
+224,000 vol
$0.28 each
4,488,000
Filed 2018-08-28
Tx date 2018-08-24
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$49,035
+175,000 vol
$0.2802 each
4,264,000
Filed 2018-08-24
Tx date 2018-08-20
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$50,187
+186,500 vol
$0.2691 each
2,116,000
Filed 2018-08-24
Tx date 2018-08-21
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$217,499
+750,000 vol
$0.29 each
3,311,000
Filed 2018-08-24
Tx date 2018-08-23
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$80,621
+281,500 vol
$0.2864 each
4,089,000
Filed 2018-08-24
Tx date 2018-08-21
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$125,222
+445,000 vol
$0.2814 each
2,561,000
Filed 2018-08-24
Tx date 2018-08-22
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$142,545
+496,500 vol
$0.2871 each
3,807,500
Filed 2018-08-22
Tx date 2018-08-21
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$10,080
+42,000 vol
$0.24 each
1,077,627
Filed 2018-08-20
Tx date 2018-05-01
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-20
Tx date 2018-08-15
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+1,000,000 vol
1,000,000
Filed 2018-08-20
Tx date 2018-08-17
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$215,690
+769,500 vol
$0.2803 each
1,929,500
Filed 2018-08-20
Tx date 2018-08-15
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$38,720
+176,000 vol
$0.22 each
176,000
Filed 2018-08-20
Tx date 2018-05-01
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-20
Tx date 2018-08-17
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$9,450
+35,000 vol
$0.27 each
1,035,627
Filed 2018-08-20
Tx date 2018-08-16
$ASP
Acerus Pharmaceuticals Corporation
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$230,157
+984,000 vol
$0.2339 each
1,160,000
Filed 2018-08-15
Tx date 2018-08-15
$ASP
Acerus Pharmaceuticals Corporation
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$5,880
+28,000 vol
$0.21 each
487,900
Filed 2018-08-15
Tx date 2018-08-15
$ASP
Acerus Pharmaceuticals Corporation
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$15,840
+72,000 vol
$0.22 each
559,900
Filed 2018-05-17
Tx date 2015-12-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-05-17
Tx date 2015-12-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
57,500
Filed 2018-05-17
Tx date 2015-12-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-05-17
Tx date 2015-12-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+316,598 vol
2,701,598
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+316,598 vol
1,316,598
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$20,412
+72,900 vol
$0.28 each
459,900
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$81.00
+300 vol
$0.27 each
26,800
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$7,287
+26,500 vol
$0.275 each
26,500
Filed 2018-03-26
Tx date 2017-06-01
$ASP
Acerus Pharmaceuticals Corporation
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+334,863 vol
1,634,863
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+225,272 vol
1,225,272
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
1,175,000
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+75,000 vol
1,075,000
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options

+100,000 vol
475,000
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
525,000
Filed 2018-03-26
Tx date 2018-03-22
$ASP
Acerus Pharmaceuticals Corporation
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$99,184
+374,000 vol
$0.2652 each
1,000,627
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
400,000
Filed 2018-03-26
Tx date 2018-03-23
$ASP
Acerus Pharmaceuticals Corporation
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
400,000
Filed 2018-03-21
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+200,000 vol
300,000
Filed 2017-12-27
Tx date 2017-12-27
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$8,339
+27,900 vol
$0.2989 each
3,030,000
Filed 2017-12-27
Tx date 2017-12-27
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$14,324
+50,000 vol
$0.2865 each
3,002,100
Filed 2017-12-21
Tx date 2017-06-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-12-21
Tx date 2017-12-18
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$14,910
+49,700 vol
$0.30 each
49,700
Filed 2017-12-11
Tx date 2017-12-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$72,000
+200,000 vol
$0.36 each
200,000
Filed 2017-12-11
Tx date 2017-12-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-12-01
Tx date 2017-11-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,845
+28,500 vol
$0.17 each
936,500
Filed 2017-12-01
Tx date 2017-11-27
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$40,929
+194,900 vol
$0.21 each
1,426,400
Filed 2017-12-01
Tx date 2017-11-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,200
+16,000 vol
$0.20 each
1,231,500
Filed 2017-12-01
Tx date 2017-11-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$390.00
+2,000 vol
$0.195 each
1,215,500
Filed 2017-12-01
Tx date 2017-11-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$29,202
+157,000 vol
$0.186 each
1,213,500
Filed 2017-12-01
Tx date 2017-11-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$20,760
+120,000 vol
$0.173 each
1,056,500
Filed 2017-11-21
Tx date 2017-11-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$5,440
+32,000 vol
$0.17 each
191,000
Filed 2017-11-21
Tx date 2017-11-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$33,320
+196,000 vol
$0.17 each
387,000
Filed 2017-11-20
Tx date 2017-11-15
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$300.00
+2,000 vol
$0.15 each
2,947,000
Filed 2017-11-20
Tx date 2017-11-17
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$918.00
+5,100 vol
$0.18 each
2,952,100
Filed 2017-11-17
Tx date 2017-11-14
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,812
+12,500 vol
$0.145 each
149,500
Filed 2017-11-17
Tx date 2017-11-15
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,330
+9,500 vol
$0.14 each
159,000
Filed 2017-11-17
Tx date 2017-11-13
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$8,680
+62,000 vol
$0.14 each
137,000
Filed 2017-11-15
Tx date 2017-11-15
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,950
+33,000 vol
$0.15 each
33,000
Filed 2017-11-15
Tx date 2016-07-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-11-13
Tx date 2017-11-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$18,135
+139,500 vol
$0.13 each
2,848,000
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,620
+13,500 vol
$0.12 each
2,708,500
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$60,000
+500,000 vol
$0.12 each
2,385,000
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$62,500
+500,000 vol
$0.125 each
2,695,000
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$60,000
+500,000 vol
$0.12 each
1,000,000
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$9,750
+75,000 vol
$0.13 each
75,000
Filed 2017-11-13
Tx date 2017-06-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$60,000
+500,000 vol
$0.12 each
1,300,000
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$60,000
+500,000 vol
$0.12 each
1,000,000
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$24,000
+200,000 vol
$0.12 each
1,000,000
Filed 2017-11-13
Tx date 2017-11-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$60,000
+500,000 vol
$0.12 each
800,000
Filed 2017-11-13
Tx date 2017-11-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$13,095
+97,000 vol
$0.135 each
2,945,000
Filed 2017-09-01
Tx date 2017-08-28
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$30,245
+263,000 vol
$0.115 each
908,000
Filed 2017-06-06
Tx date 2017-06-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+500,000 vol
500,000
Filed 2017-06-06
Tx date 2017-06-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-06-02
Tx date 2017-06-02
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,680
+39,000 vol
$0.12 each
424,500
Filed 2017-05-24
Tx date 2017-05-17
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+900,000 vol
8,048,325
Filed 2017-03-24
Tx date 2017-03-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$2,127
+18,500 vol
$0.115 each
626,627
Filed 2017-03-24
Tx date 2017-03-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$11,040
+96,000 vol
$0.115 each
608,127
Filed 2017-03-24
Tx date 2017-03-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$1,782
+15,500 vol
$0.115 each
512,127
Filed 2017-03-14
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+200,000 vol
300,000
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+300,000 vol
800,000
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$11,000
+100,000 vol
$0.11 each
385,500
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+600,000 vol
1,885,000
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+200,000 vol
425,000
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options

+200,000 vol
375,000
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+200,000 vol
300,000
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+2,000,000 vol
7,148,325
Filed 2017-03-13
Tx date 2017-03-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+200,000 vol
500,000
Filed 2016-12-08
Tx date 2016-12-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$11,875
+95,000 vol
$0.125 each
2,195,000
Filed 2016-11-23
Tx date 2016-11-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$14,729
+100,000 vol
$0.1473 each
285,500
Filed 2016-11-14
Tx date 2016-11-14
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$13,000
+100,000 vol
$0.13 each
2,100,000
Filed 2016-11-08
Tx date 2016-11-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
$90,000
+500,000 vol
$0.18 each
500,000
Filed 2016-11-08
Tx date 2016-11-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-11-04
Tx date 2016-11-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,550
+15,000 vol
$0.17 each
40,000
Filed 2016-08-23
Tx date 2016-08-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+325,000 vol
5,148,325
Filed 2016-08-23
Tx date 2016-08-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$9,600
+60,000 vol
$0.16 each
185,500
Filed 2016-08-22
Tx date 2016-08-19
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$49,000
+350,000 vol
$0.14 each
645,000
Filed 2016-08-17
Tx date 2016-08-16
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$90,000
+1,000,000 vol
$0.09 each
2,000,000
Filed 2016-08-12
Tx date 2016-08-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+300,000 vol
300,000
Filed 2016-08-12
Tx date 2016-07-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-08-12
Tx date 2016-08-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
100,000
Filed 2016-08-12
Tx date 2016-07-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-08-12
Tx date 2016-08-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,250
+25,000 vol
$0.09 each
25,000
Filed 2016-08-12
Tx date 2015-06-26
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2016-07-27
Tx date 2016-07-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
1,000,000
Filed 2016-06-22
Tx date 2016-06-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,080
+16,000 vol
$0.13 each
291,000
Filed 2016-06-22
Tx date 2016-06-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,900
+100,000 vol
$0.129 each
275,000
Filed 2016-06-22
Tx date 2016-06-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$7,800
+60,000 vol
$0.13 each
125,500
Filed 2016-06-10
Tx date 2016-06-09
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-175,603.80
-1,463,365 vol
$0.12 each
20,913,418
Filed 2016-06-10
Tx date 2016-06-08
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-40,560
-312,000 vol
$0.13 each
22,376,783
Filed 2016-06-10
Tx date 2016-06-08
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-11,000
-88,000 vol
$0.125 each
22,688,783
Filed 2016-06-10
Tx date 2016-06-07
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-202.50
-1,500 vol
$0.135 each
22,776,783
Filed 2016-06-10
Tx date 2016-06-07
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-47,645
-366,500 vol
$0.13 each
22,778,283
Filed 2016-06-10
Tx date 2016-06-03
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,417.50
-10,500 vol
$0.135 each
23,144,783
Filed 2016-06-10
Tx date 2016-06-03
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-2,622
-20,000 vol
$0.1311 each
23,155,283
Filed 2016-06-10
Tx date 2016-06-03
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-26,260
-202,000 vol
$0.13 each
23,175,283
Filed 2016-06-10
Tx date 2016-06-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-13,702.50
-101,500 vol
$0.135 each
23,377,283
Filed 2016-06-10
Tx date 2016-06-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-25,225.10
-193,000 vol
$0.1307 each
23,478,783
Filed 2016-06-10
Tx date 2016-06-01
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-26,715
-205,500 vol
$0.13 each
23,671,783
Filed 2016-06-10
Tx date 2016-05-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-652.50
-4,500 vol
$0.145 each
23,877,283
Filed 2016-06-10
Tx date 2016-05-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-22,680
-162,000 vol
$0.14 each
23,881,783
Filed 2016-06-10
Tx date 2016-05-25
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-2,100
-14,000 vol
$0.15 each
24,043,783
Filed 2016-06-10
Tx date 2016-05-25
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,160
-8,000 vol
$0.145 each
24,057,783
Filed 2016-06-10
Tx date 2016-05-25
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-25,311
-177,000 vol
$0.143 each
24,065,783
Filed 2016-06-10
Tx date 2016-05-25
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-16,100
-115,000 vol
$0.14 each
24,242,783
Filed 2016-06-10
Tx date 2016-05-25
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-3,808
-28,000 vol
$0.136 each
24,357,783
Filed 2016-06-10
Tx date 2016-05-25
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-6,345
-47,000 vol
$0.135 each
24,385,783
Filed 2016-06-10
Tx date 2016-05-25
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-14,430
-111,000 vol
$0.13 each
24,432,783
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,520
-9,500 vol
$0.16 each
24,543,783
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-2,340
-15,000 vol
$0.156 each
24,553,283
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-17,592.50
-113,500 vol
$0.155 each
24,568,283
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-17,475
-116,500 vol
$0.15 each
24,681,783
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-8,047.50
-55,500 vol
$0.145 each
24,798,283
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-5,760
-40,000 vol
$0.144 each
24,853,783
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-10,850
-77,500 vol
$0.14 each
24,893,783
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-810.00
-6,000 vol
$0.135 each
24,971,283
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-2,620
-20,000 vol
$0.131 each
24,977,283
Filed 2016-06-10
Tx date 2016-05-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,690
-13,000 vol
$0.13 each
24,997,283
Filed 2016-06-10
Tx date 2016-05-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-16,275
-105,000 vol
$0.155 each
25,010,283
Filed 2016-06-10
Tx date 2016-05-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-43,650
-291,000 vol
$0.15 each
25,115,283
Filed 2016-06-10
Tx date 2016-05-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-59,914.80
-396,000 vol
$0.1513 each
Filed 2016-06-10
Tx date 2016-05-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-59,914.80
-396,000 vol
$0.1513 each
Filed 2016-06-10
Tx date 2016-05-19
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-23,471.50
-149,500 vol
$0.157 each
25,406,283
Filed 2016-06-10
Tx date 2016-05-19
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,650
-10,000 vol
$0.165 each
25,555,783
Filed 2016-06-10
Tx date 2016-05-19
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-12,880
-80,500 vol
$0.16 each
25,565,783
Filed 2016-06-10
Tx date 2016-05-19
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-11,547.50
-74,500 vol
$0.155 each
25,646,283
Filed 2016-06-10
Tx date 2016-05-19
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-27,825
-185,500 vol
$0.15 each
25,720,783
Filed 2016-06-10
Tx date 2016-05-16
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-8,840
-52,000 vol
$0.17 each
25,906,283
Filed 2016-06-10
Tx date 2016-05-16
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-47,025
-285,000 vol
$0.165 each
25,958,283
Filed 2016-06-10
Tx date 2016-05-16
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-18,080
-113,000 vol
$0.16 each
26,243,283
Filed 2016-06-10
Tx date 2016-05-16
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-7,750
-50,000 vol
$0.155 each
26,356,283
Filed 2016-06-10
Tx date 2016-05-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-10,725
-65,000 vol
$0.165 each
26,406,283
Filed 2016-06-10
Tx date 2016-05-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,920
-12,000 vol
$0.16 each
26,471,283
Filed 2016-06-10
Tx date 2016-05-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-2,635
-17,000 vol
$0.155 each
26,483,283
Filed 2016-06-10
Tx date 2016-05-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-16,425
-109,500 vol
$0.15 each
26,500,283
Filed 2016-06-10
Tx date 2016-05-11
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-22,620
-156,000 vol
$0.145 each
26,609,783
Filed 2016-06-10
Tx date 2016-05-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-2,635
-15,500 vol
$0.17 each
26,765,783
Filed 2016-06-10
Tx date 2016-05-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-3,630
-22,000 vol
$0.165 each
26,781,283
Filed 2016-06-10
Tx date 2016-05-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-20,480
-128,000 vol
$0.16 each
26,803,283
Filed 2016-06-10
Tx date 2016-05-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-12,400
-80,000 vol
$0.155 each
26,931,283
Filed 2016-06-10
Tx date 2016-05-10
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-47,550
-317,000 vol
$0.15 each
27,011,283
Filed 2016-06-10
Tx date 2016-03-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-701.25
-8,500 vol
$0.0825 each
Filed 2016-06-10
Tx date 2016-03-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-701.25
-8,500 vol
$0.0825 each
Filed 2016-06-10
Tx date 2016-03-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-54,280
-678,500 vol
$0.08 each
Filed 2016-06-10
Tx date 2016-03-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-54,280
-678,500 vol
$0.08 each
Filed 2016-06-10
Tx date 2016-03-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,330
-14,000 vol
$0.095 each
27,328,283
Filed 2016-06-10
Tx date 2016-03-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-16,830
-187,000 vol
$0.09 each
27,342,283
Filed 2016-06-10
Tx date 2016-03-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,925
-22,000 vol
$0.0875 each
27,529,283
Filed 2016-06-10
Tx date 2016-03-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-7,650
-90,000 vol
$0.085 each
27,551,283
Filed 2016-06-10
Tx date 2016-03-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-701.25
-8,500 vol
$0.0825 each
27,641,283
Filed 2016-06-10
Tx date 2016-03-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-54,280
-678,500 vol
$0.08 each
27,649,783
Filed 2016-06-10
Tx date 2016-03-17
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-8,455
-89,000 vol
$0.095 each
28,328,283
Filed 2016-06-10
Tx date 2016-03-17
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-24,795
-275,500 vol
$0.09 each
28,417,283
Filed 2016-06-10
Tx date 2016-03-17
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-19,975
-235,000 vol
$0.085 each
28,692,783
Filed 2016-06-10
Tx date 2016-03-17
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-32,040
-400,500 vol
$0.08 each
28,927,783
Filed 2016-05-18
Tx date 2016-05-13
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately
$10,246,388
+51,437,691 vol
$0.1992 each
102,518,784
Filed 2016-05-17
Tx date 2016-05-13
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately

-36,979,391 vol
0
Filed 2016-03-31
Tx date 2016-03-28
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$7,400
+74,000 vol
$0.10 each
51,081,093
Filed 2016-03-31
Tx date 2016-03-28
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$368,000
+2,944,000 vol
$0.125 each
51,007,093
Filed 2016-03-31
Tx date 2016-03-28
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$31,780
+227,000 vol
$0.14 each
496,627
Filed 2016-03-31
Tx date 2016-03-28
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$1,690
+13,000 vol
$0.13 each
269,627
Filed 2016-03-31
Tx date 2016-03-28
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$1,200
+10,000 vol
$0.12 each
256,627
Filed 2016-03-30
Tx date 2016-03-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,500
+45,000 vol
$0.10 each
65,500
Filed 2016-03-28
Tx date 2016-03-24
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$25,840
+272,000 vol
$0.095 each
48,063,093
Filed 2016-03-28
Tx date 2016-03-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$17,010
+189,000 vol
$0.09 each
47,791,093
Filed 2016-03-09
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$10,000
+100,000 vol
$0.10 each
100,000
Filed 2016-03-09
Tx date 2015-12-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Sherman, Jeffrey Dennis
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
225,000
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+2,000,000 vol
4,823,325
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Reininghaus, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
1,392,500
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
50 - Grant of options

+100,000 vol
154,865
Filed 2016-03-08
Tx date 2015-12-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
54,865
Filed 2016-03-08
Tx date 2015-12-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
12,500
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options

+100,000 vol
175,000
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Hawkins, Matthew
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+950,000 vol
1,585,000
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
225,000
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
100,000
Filed 2016-03-08
Tx date 2015-12-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bumby, Michael Scott
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+400,000 vol
600,000
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+950,000 vol
1,285,000
Filed 2016-03-08
Tx date 2016-03-04
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
100,000
Filed 2016-03-08
Tx date 2015-06-26
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-01-08
Tx date 2016-01-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-2,080
-13,000 vol
$0.16 each
29,328,283
Filed 2016-01-08
Tx date 2016-01-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-6,510
-42,000 vol
$0.155 each
29,341,283
Filed 2016-01-08
Tx date 2016-01-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-29,250
-195,000 vol
$0.15 each
29,383,283
Filed 2016-01-08
Tx date 2016-01-05
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-5,130
-28,500 vol
$0.18 each
29,578,283
Filed 2016-01-08
Tx date 2016-01-05
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-262.50
-1,500 vol
$0.175 each
29,606,783
Filed 2016-01-08
Tx date 2016-01-05
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-4,590
-27,000 vol
$0.17 each
29,608,283
Filed 2016-01-08
Tx date 2016-01-05
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-11,440
-71,500 vol
$0.16 each
29,635,283
Filed 2016-01-08
Tx date 2016-01-05
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,705
-11,000 vol
$0.155 each
29,706,783
Filed 2016-01-08
Tx date 2016-01-05
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-16,575
-110,500 vol
$0.15 each
29,717,783
Filed 2016-01-04
Tx date 2015-12-31
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$-62,400
-520,000 vol
$0.12 each
36,979,391
Filed 2016-01-03
Tx date 2015-12-30
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$-40,152
-280,000 vol
$0.1434 each
37,499,391
Filed 2015-12-30
Tx date 2015-12-29
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$-28,940
-200,000 vol
$0.1447 each
37,779,391
Filed 2015-12-29
Tx date 2015-12-29
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,200
+28,000 vol
$0.15 each
295,000
Filed 2015-12-29
Tx date 2015-12-29
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,739
+12,000 vol
$0.145 each
267,000
Filed 2015-12-29
Tx date 2015-12-22
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$11,900
+85,000 vol
$0.14 each
255,000
Filed 2015-12-29
Tx date 2015-12-22
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$16,675
+115,000 vol
$0.145 each
170,000
Filed 2015-12-25
Tx date 2015-12-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
230,000
Filed 2015-12-23
Tx date 2015-12-20
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
57,500
Filed 2015-12-23
Tx date 2015-12-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,575
+9,000 vol
$0.175 each
20,500
Filed 2015-12-23
Tx date 2015-12-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,190
+7,000 vol
$0.17 each
11,500
Filed 2015-12-21
Tx date 2015-12-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
37,979,391
Filed 2015-09-24
Tx date 2015-09-22
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Pfeffer, Matthew Jonathan
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$8,000
+20,000 vol
$0.40 each
20,000
Filed 2015-09-24
Tx date 2013-11-27
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Pfeffer, Matthew Jonathan
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2015-09-24
Tx date 2015-09-23
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$8,000
+20,000 vol
$0.40 each
55,000
Filed 2015-09-24
Tx date 2015-09-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,905
+7,000 vol
$0.415 each
35,000
Filed 2015-09-24
Tx date 2015-09-21
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,260
+3,000 vol
$0.42 each
28,000